Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)-Reference-Cited by-同舟云学术

Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)

Published:2019-12-04 Issue:4 Volume:60 Page:444-452
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Sharma Manish R.¹,Mehrotra Shailly²,Gray Elizabeth¹,Wu Kehua¹,Barry William T.³,Hudis Clifford⁴,Winer Eric P.⁵,Lyss Alan P.⁶,Toppmeyer Deborah L.⁷,Moreno‐Aspitia Alvaro⁸,Lad Thomas E.⁹,Velasco Mario¹⁰,Overmoyer Beth⁵,Rugo Hope S.¹¹,Ratain Mark J.¹,Gobburu Jogarao V.²

Affiliation:

1. The University of Chicago Chicago Illinois USA

2. Center for Translational MedicineUniversity of Maryland Baltimore Maryland USA

3. Alliance Statistics and Data CenterDana‐Farber Cancer Institute Boston Massachusetts USA

4. Memorial Sloan Kettering Cancer Center New York New York USA

5. Dana‐Farber/Partners CancerCare/Harvard Cancer Center Boston Massachusetts USA

6. Heartland Cancer Research NCORP St. Louis Missouri USA

7. Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA

8. Mayo Clinic Jacksonville Florida USA

9. John H. Stroger Jr Hospital of Cook County Chicago Illinois USA

10. Decatur Memorial Hospital/Cancer Care Specialists of Illinois/Heartland Cancer Research NCORP Decatur Illinois USA

11. University of California San Francisco San Francisco California USA

Funder

National Cancer Institute

National Institute of General Medical Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1559

Reference15 articles.

1. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): A systematic review

2. Cancer pain and its impact on diagnosis, survival and quality of life

3. Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy

4. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

5. Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study;Frontiers in Pharmacology;2023-07-04

2. Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912);Supportive Care in Cancer;2021-06-27

3. A systematic review of modeling and simulation approaches in designing targeted treatment technologies for Leukemia Cancer in low and middle income countries;Mathematical Biosciences and Engineering;2021

4. Predisposing Factors for the Development of Chemotherapy-Induced Peripheral Neuropathy (CIPN);Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy;2021

5. Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial;Frontiers in Oncology;2020-10-09